Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
Strengths
  • Historically, the company has been releasing figures that are above expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
INNATE PHARMA-5.54%514
LONZA GROUP13.73%31 009
CELLTRION, INC.22.13%25 160
IQVIA HOLDINGS INC.-33.52%20 797
SEATTLE GENETICS, INC.1.97%19 875
INCYTE CORPORATION-11.74%15 874
GALAPAGOS NV-6.43%12 893
ALNYLAM PHARMACEUTICALS, IN..-8.12%12 308
MODERNA, INC.78.12%11 041
QIAGEN N.V.19.14%9 469
ICON PUBLIC LIMITED COMPANY-24.17%7 293
BIO-TECHNE CORPORATION-15.09%7 272
HANGZHOU TIGERMED CONSULTIN..-1.46%6 779
IONIS PHARMACEUTICALS, INC.-19.70%6 582
ACADIA PHARMACEUTICALS INC.-4.72%6 563
PHARMARON BEIJING CO., LTD.3.00%6 405
More Results
Financials (EUR)
Sales 2019 90,6 M
EBIT 2019 -16,3 M
Net income 2019 -9,95 M
Finance 2019 49,3 M
Yield 2019 -
P/E ratio 2019 -41,1x
P/E ratio 2020 -114x
EV / Sales2019 4,40x
EV / Sales2020 3,52x
Capitalization 448 M
Upcoming event on INNATE PHARMA
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes